Brett Howell is the President of the DILIsym Services division of Simulations Plus, which is developing and using DILIsym and other software tools to improve the development of safer and more effective drug therapies. He is also an associate director of the DILI-sim Initiative since its inception in 2011. Dr. Howell focuses on company management and operations, sales and marketing, product design, and also helps guide the architecture and consulting use of various QST platforms such as DILIsym and RENAsym.
Dr. Howell has published over 30 scientific papers in the areas of PBPK/PD modeling, in vitro toxicity testing, novel drug delivery systems, and drug safety. He has given invited scientific presentations at numerous national and international meetings, including the Society of Toxicology annual meeting, the Japanese Society of Toxicology annual meeting, the annual FDA/AASLD Drug-Induced Liver Injury meeting, and the American Conference on Pharmacometrics (ACOP) annual meeting. He serves on the editorial board for the prominent Quantitative Systems Pharmacology (QSP) journal, “CPT: Pharmacometrics & Systems Pharmacology,” published by the American Society for Clinical Pharmacology and Therapeutics.
Dr. Howell holds a Ph.D. in chemical engineering from the University of Florida and Bachelor of Science degrees in chemical engineering and textile engineering from North Carolina State University.